Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Emerging Treatments and Technologies

The Effect of Vitamin Therapy on the Progression of Coronary Artery Atherosclerosis Varies by Haptoglobin Type in Postmenopausal Women

  1. Andrew P. Levy, MD, PHD1,
  2. Paula Friedenberg, MS2,
  3. Rachel Lotan, PHD1,
  4. Pamela Ouyang, MD3,
  5. Mark Tripputi, MS2,
  6. Lyall Higginson, MD4,
  7. Frederick R. Cobb, MD5,
  8. Jean-Claude Tardif, MD6,
  9. Vera Bittner, MD7 and
  10. Barbara V. Howard, PHD8
  1. 1Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
  2. 2George Washington University Biostatistics Center, Washington, DC
  3. 3Division of Cardiology, Johns Hopkins Bayview Medical Center, Baltimore, Maryland
  4. 4University of Ottawa Heart Institute, Ottawa, Ontario, Canada
  5. 5Duke Center for Living, Duke University, Durham, North Carolina
  6. 6Montreal Heart Institute, Montreal, Quebec, Canada
  7. 7Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, Alabama
  8. 8Department of Cardiology, Medstar Research Institute, Washington, DC
  1. Address correspondence and reprint requests to Dr. Andrew P. Levy, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel. E-mail: alevy{at}tx.technion.ac.il
Diabetes Care 2004 Apr; 27(4): 925-930. https://doi.org/10.2337/diacare.27.4.925
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Abstract

OBJECTIVE—Antioxidant trials have not demonstrated efficacy in slowing cardiovascular disease but could not rule out benefit for specific patient subgroups. Antioxidant therapy reduces LDL oxidizability in haptoglobin 1 allele homozygotes (Hp 1-1), but not in individuals with the haptoglobin 2 allele (Hp 2-1 or Hp 2-2). We therefore hypothesized that haptoglobin type would be predictive of the effect of vitamin therapy on coronary atherosclerosis as assessed by angiography.

RESEARCH DESIGN AND METHODS—We tested this hypothesis in the Women’s Angiographic Vitamin and Estrogen (WAVE) trial, a prospective angiographic study of vitamins C and E with or without hormone replacement therapy (HRT) in postmenopausal women. Haptoglobin type was determined in 299 women who underwent baseline and follow-up angiography. The annualized change in the minimum luminal diameter (MLD) was examined in analyses stratified by vitamin use, haptoglobin type, and diabetes status.

RESULTS—We found a significant benefit on the change in MLD with vitamin therapy as compared with placebo in Hp 1-1 subjects (0.079 ± 0.040 mm, P = 0.049). This benefit was more marked in diabetic subjects (0.149 ± 0.064 mm, P = 0.021). On the other hand, there was a trend toward a more rapid decrease in MLD with vitamin therapy in Hp 2-2 subjects, which was more marked in diabetic subjects (0.128 ± 0.057 mm, P = 0.027). HRT had no effect on these outcomes.

CONCLUSIONS—The relative benefit or harm of vitamin therapy on the progression of coronary artery stenoses in women in the WAVE study was dependent on haptoglobin type. This influence of haptoglobin type seemed to be stronger in women with diabetes.

  • HRT, hormone replacement therapy
  • MLD, minimum luminal diameter
  • WAVE, Women’s Angiographic Vitamin and Estrogen

Oxidative stress is enhanced within the wall of atherosclerotic arteries (1–3). There exists considerable evidence from animal studies that antioxidant vitamins can slow or prevent the development of atherosclerotic lesions (4,5). Numerous mechanisms have been demonstrated for this protective effect including the prevention of LDL oxidation within the vessel wall (6). However, in humans, antioxidant therapy has not been shown to slow the progression of atherosclerotic coronary artery disease (7–9). On the contrary, several prospective angiographic studies have demonstrated that antioxidant therapy may be associated with a more rapid progression of atherosclerosis, potentially due to a deleterious effect on the lipid profile (8,10,11) or perhaps the ability of these antioxidants to become pro-oxidants under certain conditions (12–18).

This discrepancy between the animal and human studies may be the result of functional differences in polymorphic loci, which modulate oxidative stress. Haptoglobin is an antioxidant protein by virtue of its ability to prevent hemoglobin-induced tissue oxidation (19,20). The haptoglobin gene locus at chromosome 16q22 is polymorphic, with two general classes of functionally distinct alleles denoted 1 and 2 (21). This polymorphism exists only in man. The 1 allele in humans is >90% homologous to the 1 allele existing in all other animals. The 2 allele is present only in humans and is believed to have arisen from the 1 allele ∼100,000 years ago, early in human evolution (21). The relative frequency of the two haptoglobin alleles varies by ethnicity and race, thereby accounting for the marked differences observed in the distribution of the three possible haptoglobin types (1-1, 2-1, and 2-2) among different ethnic and racial groups. For example, in American Caucasians, 14% of the population is Hp 1-1 and 37% is Hp 2-2, whereas in American blacks 26% of the population is Hp 1-1 and 38% is Hp 2-2 (22).

The role of the haptoglobin type on the resistance of LDL to oxidation after antioxidant therapy was recently reported (23). Although there were no differences in the oxidizability of LDL between study participants with the different haptoglobin types before commencement of the study, after treatment with antioxidants, participants homozygous for the haptoglobin 1 allele (Hp 1-1) had a dramatic increase in the resistance of LDL to oxidation. However, no effect was seen in individuals homozygous for the haptoglobin 2 allele (Hp 2-2) or the heterozygote (Hp 2-1) (23).

Taken together, these studies suggest that the beneficial effect of antioxidant supplementation on progression of coronary artery disease may be limited to those individuals homozygous for the haptoglobin 1 allele. We have sought to test this hypothesis using plasma samples from the Women’s Angiographic Vitamin and Estrogen (WAVE) study (9), a prospective angiographic study of antioxidant vitamins with or without hormone replacement therapy (HRT) in postmenopausal women.

RESEARCH DESIGN AND METHODS

Description of the WAVE study

The design and methods of the WAVE trial have been previously described (9). Briefly, WAVE was a prospective, randomized, double-blind trial that enrolled 423 postmenopausal women with at least one 15–75% coronary stenosis at baseline coronary arteriography. Patients were randomly assigned in a 2 × 2 factorial design to receive either 0.625 mg/day of conjugated equine estrogen (plus 2.5 mg/day of medroxyprogesterone acetate for women who had not had a hysterectomy), matching placebo and 400 IU of vitamin E twice daily plus 500 mg of vitamin C twice daily, or placebo. The mean interval between angiograms was 2.8 ± 0.9 years. The main outcome measure of the trial was the annualized mean change in the minimum luminal diameter (MLD) from baseline to the concluding angiogram of all qualifying coronary lesions averaged for each patient. WAVE qualifying segments were defined as segments with 15–75% stenoses at baseline or new lesions at follow-up. The annualized mean change in the MLD from baseline to concluding angiogram (or to intercurrent angiogram before revascularization) was available for all WAVE qualifying lesions and averaged for each patient. Stored plasma from the baseline exam was available on 403 of 423 (95.2%) of the initial WAVE cohort.

Haptoglobin phenotyping

Haptoglobin phenotyping was performed from 10 μl of plasma by polyacrylamide gel electrophoresis according to established methods (24). A signature banding pattern is obtained from individuals who are homozygous for the 1 allele (Hp 1-1), homozygous for the 2 allele (Hp 2-2), or heterozygous at the haptoglobin locus (Hp 2-1). We have established 100% concordance between the haptoglobin phenotype as determined from plasma and the haptoglobin genotype as determined from genomic DNA by the polymerase chain reaction (25). Haptoglobin phenotyping was performed with no knowledge of the patient’s treatment status.

Statistical analysis

The Hardy-Weinberg principle of population genetics is used to determine whether two alleles are in a balanced equilibrium, indicating a lack of survival benefit for one allele relative to the other. To determine whether a population is in Hardy-Weinberg equilibrium, it is necessary to use the Hardy-Weinberg formula to calculate the genotype frequencies in the population. In this equation (p2 + 2pq + q2 = 1), p is defined as the frequency of the 1 allele and q is defined as the frequency of the 2 allele for a trait or phenotype controlled by a pair of alleles (1 and 2). In this equation, p2 is the frequency of homozygous (1-1) individuals in a population, 2pq is the frequency of heterozygous (2-1) individuals, and q2 is the frequency of homozygous 2 (2-2) individuals. To actually determine whether our study population was in Hardy-Weinberg equilibrium, the actual distribution of the three haptoglobin types in this study was compared with the distribution of the three haptoglobin types expected if the population was in Hardy-Weinberg equilibrium according to χ2 test (26).

All analyses were performed using SAS statistical software (version 8.0; SAS Institute, Cary, NC). ANCOVA or χ2 tests (as appropriate) compared baseline characteristics of patients segregated according to haptoglobin phenotype. Student’s t test was used to compare change in HDL and LDL. The effect of haptoglobin type on change in MLD was analyzed by an ANCOVA model. The differential effect of antioxidant therapy on changes in the MLD in individuals with the different haptoglobin phenotypes was assessed by an ANCOVA model, and the mean changes and SDs in each group were calculated. The baseline covariates, representing known cardiovascular disease risk factors and glycemic control, of age, hypertension, cholesterol level, diabetes status, and HbA1c were included in all models. Univariate regression with MLD as a dependent variable against HRT as well as against the hormone-vitamin interaction was not statistically significant, and, therefore, HRT was not included in the models presented. We cannot distinguish between WAVE participants with type 1 and 2 diabetes because this information was not obtained upon enrollment in WAVE and is not in the WAVE database.

RESULTS

Characteristics of the WAVE participants who had haptoglobin phenotyping and repeat angiography

There were originally 423 women enrolled in the WAVE trial, 154 of which had diabetes. The analyses presented here were performed only on those 299 participants (113 of whom had diabetes) for whom both repeat angiography and a haptoglobin type was obtained. The number of participants for whom repeat angiography and/or haptoglobin phenotype was obtained is described in Table 1. The distribution of the haptoglobin types of those individuals who enrolled in WAVE but did not undergo repeat angiography was not different from those who did undergo repeat angiography.

In the population undergoing repeat angiography, the distribution of the three haptoglobin phenotypes in the entire cohort and in those individuals with diabetes was in Hardy-Weinberg equilibrium. There were no significant differences in the entire cohort or in the diabetic subgroup with respect to baseline demographic, angiographic, or clinical characteristics in participants with the three different haptoglobin phenotypes (Table 2).

Changes in the MLD as a function of haptoglobin phenotype

In the entire study population, there was no difference in the change in MLD based on haptoglobin phenotype (P = 0.19). The average (±SD) change in MLD was −0.047 ± 0.199 for Hp 1-1, −0.026 ± 0.110 for Hp 2-1, and −0.048 ± 0.153 for Hp 2-2.

In the diabetic study population, there also was no difference in the change in the MLD based on haptoglobin phenotype (P = 0.12). The average (±SD) change in MLD was −0.071 ± 0.207 for Hp 1-1, −0.037 ± 0.100 for Hp 2-1, and −0.110 ± 0.188 for Hp 2-2.

Changes in the MLD as a function of haptoglobin phenotype and vitamin therapy

The means and SDs for each vitamin/haptoglobin type, both before and after adjustment for baseline covariates, are shown in Table 3. Vitamin supplementation had a differential effect on MLD after adding a vitamin use/haptoglobin type interaction into the model (P = 0.035 for the interaction term between haptoglobin type and vitamin use on the change in the MLD). There was a significant benefit acquired on the change in the MLD with vitamin therapy as compared to placebo in individuals with Hp 1-1 (P = 0.049), whereas there was no significant benefit seen in Hp 2-1 and Hp 2-2 individuals. In Hp 2-2, there was a nonsignificant trend suggesting a negative effect of vitamin therapy compared with placebo. After adjusting for baseline covariates (age, hypertension, cholesterol, and diabetes status), the relative benefit or harm of vitamin therapy in Hp 1-1 or Hp 2-2 individuals, as compared with placebo, was unchanged. The means and SDs for each vitamin/haptoglobin type in the diabetic cohort, both before and after adjustment for baseline covariates, are shown in Table 3. This interaction of haptoglobin phenotype and vitamin therapy upon coronary artery stenosis progression was even more pronounced in the diabetic cohort (P = 0.003 for the interaction term between haptoglobin type and vitamin use on the change in the MLD). Not only was there a significant benefit demonstrated from vitamin therapy compared with placebo in Hp 1-1 individuals, but there was also a significant deleterious effect on MLD in those individuals with Hp 2-2 both before and after adjustment for baseline covariates (age, hypertension, cholesterol, and HbA1c) compared with placebo. Moreover, we found a statistically significant trend effect between the number of haptoglobin 1 alleles and the change in MLD in diabetic subjects who were on vitamin therapy. In this group, the change in MLD had a significant linear association with the number of haptoglobin 1 alleles as described by linear regression analysis with adjustment for baseline covariates (P = 0.005). HRT had no effect on these outcome measurements, and univariate regression with MLD as a dependent variable against the HRT-vitamin interaction was not statistically significant.

Changes in lipid profile with vitamin therapy

Previous studies have suggested that antioxidant therapy may have a negative impact on the lipid profile and on the activity of lipid-lowering drugs (8,11). In the entire cohort, there was no significant difference in the change in LDL or HDL during the course of the study in those individuals receiving vitamin therapy or placebo. Moreover, there was no significant difference in the net change in LDL or HDL in any haptoglobin subgroup with or without diabetes (Table 4).

CONCLUSIONS

Although antioxidant therapy in animals has shown promise in slowing the progression of atherosclerotic lesions (4,5), prospective angiographic studies in humans have failed to corroborate these findings (7–9). In the original report of the overall results from the WAVE study, antioxidant vitamins were not shown to provide cardiovascular benefit; instead, a potential for harm was suggested (9). We have demonstrated one possible explanation for this paradox here, namely that the benefit of antioxidant therapy with vitamin C and E on progressive coronary artery stenosis may be restricted to women with the Hp 1-1 phenotype. These data are consistent with recent studies showing that antioxidant therapy only had a significant effect in lowering of LDL in Hp 1-1 individuals (23). It should be stressed that these findings were most prominent in diabetic subjects. Furthermore, only ∼17% of the original cohort (Hp 1-1 individuals) could have derived benefit from vitamin C and E therapy, whereas ∼37% of the original cohort (Hp 2-2 individuals) could have experienced harm from vitamin C and E therapy.

Why might vitamin E and vitamin C therapy be harmful in some haptoglobin types? Our results do not support a mechanism based on vitamin-induced differences in the lipid profile (8,11). One potential explanation is related to the pro-oxidant capacity of vitamin C in the presence of iron (12,14,16,17). Vitamin C promotes the reduction of Fe3+ to Fe2+ and consequently promotes the formation of hydroxyl radicals by the Fenton reaction (12,14). In the process, vitamin C is oxidized to dehydroascorbate and becomes a pro-oxidant. Serum levels of iron are highest in Hp 2-2 individuals (27). Serum levels of vitamin C are also dependent on haptoglobin type; the lowest levels occur in Hp 2-2 individuals (28). It has been proposed that the lower levels of vitamin C in Hp 2-2 individuals are due to an increased oxidation of vitamin C (28). Supplemental vitamin C may not be beneficial to individuals with Hp 2-2 because it may result in increased production of oxidized vitamin C. The fundamental reason why vitamin C is more rapidly consumed and converted into a pro-oxidant in Hp 2-2 individuals is not altered by vitamin therapy.

Why should the haptoglobin-dependent effect of vitamin therapy on angiographic stenosis be more pronounced in the WAVE diabetic subgroup? Hyperglycemia results in a marked increase in oxidative stress and directly enhances LDL oxidation (29). Mowri et al. (30) have shown that this glucose-enhanced oxidation of LDL is strictly metal-ion dependent. Similar to vitamin C, glucose auto-oxidation results in the reduction of Fe3+ to Fe2+ (30), thereby enhancing the ability of Fe to serve as a Fenton reagent and produce hydroxyl radicals. As haptoglobin type–dependent differences in oxidative stress and redox active iron seem to be most prominent in the diabetic state (20) and vitamin C therapy may be synergistic with hyperglycemia in promoting LDL oxidation via the Fenton reaction as discussed above, vitamin C supplementation in individuals with hyperglycemia and Hp 2-2 may be particularly deleterious.

Limitations in the WAVE study suggest caution in extrapolating these results immediately to the clinical arena at the present time. First, ∼20% of the original cohort recruited did not undergo follow-up angiography and only 84% of the patients assigned to the vitamin group actually took the drug, which may have produced a selection bias (9). Second, the primary end point of the WAVE study was coronary artery dimensions and not coronary events. Although coronary progression has been shown in previous angiographic trials to be a strong, independent predictor of future coronary events (31), the culprit coronary artery lesion in coronary events does not correlate well with the lesion that was most stenosed on an antecedent angiogram. Third, systemic markers of oxidative stress were not measured in WAVE; therefore, the efficacy of the antioxidant vitamins in reducing oxidation cannot be assessed (1). Fourth, the formulation of antioxidant vitamins used in WAVE was quite different from that used in other antioxidant trials (32,33). Whereas WAVE participants received 400 IU of vitamin E and 500 mg of vitamin C twice daily, in the Heart Outcomes Prevention Evaluation (HOPE) study (32), participants received only 400 mg of vitamin E once daily, and in the Heart Protection Study (HPS) (33), participants received 600 mg of vitamin E, 250 mg of vitamin C, and 20 mg of β-carotene once daily. A final limitation is that this is a subgroup analysis, resulting in significantly smaller groups for comparison, especially in the diabetes subgroup, which has a small sample size for Hp 1-1. Despite these limitations, the current study suggests that it would be prudent to reexamine several of the recent large antioxidant cardiovascular disease prevention studies for possible benefit of antioxidant therapy to certain patient subgroups based on the haptoglobin type (32,33). If the findings presented here are validated in such studies, haptoglobin typing may become a useful tool to identify individuals who will benefit from antioxidant therapy.

View this table:
  • View inline
  • View popup
Table 1—

Repeat angiography and haptoglobin type in WAVE participants

View this table:
  • View inline
  • View popup
Table 2—

Baseline characteristics

View this table:
  • View inline
  • View popup
Table 3—

Change in MLD with and without vitamins with and without adjustment for baseline covariates

View this table:
  • View inline
  • View popup
Table 4—

Change in LDL and HDL with and without vitamin therapy

Acknowledgments

This study was supported by grants from the Kennedy Leigh Charitable Trust (to A.P.L.), NHLBI Contracts NO1-HV-68165 to N01-HV-68170, and General Clinical Research Center Grant MO1-RR02715 for the WAVE study.

Footnotes

  • A.P.L. is the author of a patent that claims to predict diabetic vascular complications based on the haptoglobin phenotype. He has received no financial compensation from this patent.

    • Accepted January 6, 2004.
    • Received November 3, 2003.
  • DIABETES CARE

References

  1. ↵
    Steinberg D, Witztum JL: Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation 105:2107–2111, 2002
    OpenUrlFREE Full Text
  2. Podrez EA, Adu-Soud HM, Hazen SL: Myeloperoxidase generated oxidants and atherosclerosis. Free Radic Biol Med 28:1717–1725, 2000
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    Chisolm GM, Steinberg D: The oxidative modification hypothesis of atherogenesis: an overview. Free Radic Biol Med 28:1815–1826, 2000
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    Sparrow CP, Doebber TW, Olszewski J, Wu MS, Ventre J, Stevens KA, Chao YS: Low density lipoprotein is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol-fed rabbits by the antioxidant N, N′-diphenyl-phenylenediamine. J Clin Invest 89:1885–1891, 1992
  5. ↵
    Carew TE, Schwenke DC, Steinberg D: Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci U S A 84:7725–7729, 1987
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Diaz MN, Frei B, Vita JA, Keaney JF: Antioxidants and atherosclerotic heart disease. N Engl J Med 337:408–416, 1997
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    Walldius G, Erikson U, Olsson AG, Bergstrand L, Hadell K, Johansson J, Kaijser L, Lassvik C, Molgaard J, Nilsson S: The effect of probucol on femoral atheroslcerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 74:875–883,1994
  8. ↵
    Johansson J, Olsson AG, Bergstrand L, Elinder LS, Nilsson S, Erikson U, Molgaard J, Holme I, Walldius G: Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. Arterioscler Thromb Vasc Biol 15:1049–1056, 1995
    OpenUrlAbstract/FREE Full Text
  9. ↵
    Waters DD, Alderman EL, Hsia J, Howard BV, Cobb FR, Rogers WJ, Ouyang P, Thompson P, Tardif JC, Higginson L, Bittner V, Steffes M, Gordon DJ, Proschan M, Younes N, Verter JI: Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. JAMA 288:2432–2440, 2002
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    Waters DD: Estrogen and unstable angina: another bump for the bandwagon. J Am Coll Cardiol 39:238–240, 2002
    OpenUrlPubMedWeb of Science
  11. ↵
    Brown BG, Cheung MC, Lee AC, Zhao XQ, Chait A: Antioxidant vitamins and lipid therapy: end of a long romance? Arterioscler Thromb Vasc Biol 22:1535–1546, 2002
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Lynch SR, Cook JD: Interaction of vitamin C and iron. Ann N Y Acad Sci 355:32–44, 1980
    OpenUrlCrossRefPubMed
  13. McLaran CJ, Bett JHN, Nye JA, Halliday JW: Congestive cardiomyopathy and hemochromotosis-rapid progression possibly accelerated by excessive ingestion of ascorbic acid. Aust N Z J Med 12:187–188, 1982
    OpenUrlPubMed
  14. ↵
    Herbert V, Shaw S, Jayatilleke E: Vitamin C-driven free radical generation from iron. J Nutr 126:1213S–1220S, 1996
    OpenUrlPubMed
  15. Rehman A, Collis CS, Yang M, Kelly M, Diplock AT, Halliwell B, Rice Evans C: The effects of iron and vitamin C co-supplementation on oxidative damage to DNA in healthy volunteers. Biochem Biophys Res Commun 246:293–298, 1998
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    Proteggente AR, Rehman A, Halliwell B, Rice Evans CA: Potential problems of ascorbate and iron supplementation: prooxidant effect in vivo? Biochem Biophys Res Commun 277:535–540, 2000
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    Nappi AJ, Vass E: Comparative studies of enhanced iron-mediated production of hydroxyl radical by glutathione, cysteine, ascorbic acid and selected catechols. Biochim Biophys Acta 1336:295–302, 1997
    OpenUrlPubMed
  18. ↵
    Almaas R, Rootwelt T, Oyasaeter S, Saugstad OD: Ascorbic acid enhances hydroxyl radical formation in iron-fortified infant cereals and infant formulas. Eur J Ped 156:488–492, 1997
    OpenUrlCrossRefPubMed
  19. ↵
    Melamed-Frank M, Lache O, Enav BI, Szafranek T, Levy NS, Ricklis RM, Levy AP: Structure-function analysis of the antioxidant properties of haptoglobin. Blood 98:3693–3698, 2001
    OpenUrlAbstract/FREE Full Text
  20. ↵
    Asleh R, Marsh S, Shilkrut M, Binah O, Guetta J, Lejbowicz F, Enav B, Shehadeh N, Kanter Y, Lache O, Cohen O, Levy NS, Levy AP: Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ Res 92:1193–1200, 2003
    OpenUrlAbstract/FREE Full Text
  21. ↵
    Bowman BH, Kurosky A: Haptoglobin: the evolutionary product of duplication, unequal crossing over and point mutation. Adv Hum Genet 12:189–261, 1982
    OpenUrlPubMedWeb of Science
  22. ↵
    Langlois MR, Delanghe JR: Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 42:1589–1600, 1996
    OpenUrlAbstract/FREE Full Text
  23. ↵
    Bernard D, Christophe A, Delanghe J, Langlois M, DeBuyzere M, Comhaire F: The effect of supplementation with an antioxidant preparation on LDL-oxidation is determined by haptoglobin polymorphism. Red Rep 8:41–46, 2003
  24. ↵
    Hochberg I, Roguin A, Nikolsky E, Chanderaskekhar PV, Cohen S, Levy AP: Haptoglobin phenotype and coronary artery collaterals in diabetic patients. Atherosclerosis 161:441–446, 200
  25. ↵
    Koch W, Latz W, Eichinger M, Roguin A, Levy AP, Schomig A, Kastrati A: Genotyping of common haptoglobin polymorphism Hp1/2 based on the polymerase chain reaction. Clin Chem 277:13635–13640, 2002
    OpenUrl
  26. ↵
    Hartl D: A Primer of Population Genetics. 2nd ed. Sunderland, MA, Sinauer, 1988
  27. ↵
    Langlois MR, Martin ME, Boelaert JR, Beaumont C, Taes YE, DeBuyzere ML, Bernard DR, Neels HM, Delanghe JR: The haptoglobin 2-2 phenotype affects serum markers of iron status in healthy males. Clin Chem 46:1619–1625, 2000
    OpenUrlAbstract/FREE Full Text
  28. ↵
    Langlois MR, Delanghe JR, DeBuyzere ML, Bernard DR, Ouyang J: Effect of haptoglobin on the metabolism of vitamin C. Am J Clin Nutr 66:606–610, 1997
    OpenUrlAbstract/FREE Full Text
  29. ↵
    Tsai EC, Hirsch IB, Brunzell JD, Chait A: Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes 43:1010–1014, 1994
    OpenUrlAbstract/FREE Full Text
  30. ↵
    Mowri HO, Frei B, Keaney JF: Glucose enhancement of LDL oxidation is strictly metal ion dependent. Free Radic Biol Med 29:814–824, 2000
    OpenUrlCrossRefPubMed
  31. ↵
    Waters D, Craven TE, Lesperance J: Prognostic significance of progression of coronary atherosclerosis. Circulation 87:1067–1075, 1993
    OpenUrlAbstract/FREE Full Text
  32. ↵
    The Heart Outcomes Prevention Evaluation Study Investigators: Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 342:154–160, 2000
    OpenUrlCrossRefPubMedWeb of Science
  33. ↵
    Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of antioxidant supplementation in 20,536 high risk individuals: a randomized placebo controlled trial. Lancet 360:23–33, 2002
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Diabetes Care: 27 (4)

In this Issue

April 2004, 27(4)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Effect of Vitamin Therapy on the Progression of Coronary Artery Atherosclerosis Varies by Haptoglobin Type in Postmenopausal Women
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Effect of Vitamin Therapy on the Progression of Coronary Artery Atherosclerosis Varies by Haptoglobin Type in Postmenopausal Women
Andrew P. Levy, Paula Friedenberg, Rachel Lotan, Pamela Ouyang, Mark Tripputi, Lyall Higginson, Frederick R. Cobb, Jean-Claude Tardif, Vera Bittner, Barbara V. Howard
Diabetes Care Apr 2004, 27 (4) 925-930; DOI: 10.2337/diacare.27.4.925

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

The Effect of Vitamin Therapy on the Progression of Coronary Artery Atherosclerosis Varies by Haptoglobin Type in Postmenopausal Women
Andrew P. Levy, Paula Friedenberg, Rachel Lotan, Pamela Ouyang, Mark Tripputi, Lyall Higginson, Frederick R. Cobb, Jean-Claude Tardif, Vera Bittner, Barbara V. Howard
Diabetes Care Apr 2004, 27 (4) 925-930; DOI: 10.2337/diacare.27.4.925
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • CONCLUSIONS
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Autologous Umbilical Cord Blood Transfusion in Young Children With Type 1 Diabetes Fails to Preserve C-Peptide
  • Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes
  • Diabetes Antibody Standardization Program
Show more Emerging Treatments and Technologies

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.